Status:
UNKNOWN
Effect of High-Dose NAC on Patients With DPN
Lead Sponsor:
Ain Shams University
Conditions:
Diabetic Neuropathies
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
The aim of the current study is to evaluate the efficacy and safety of high dose oral NAC (2400 mg/day divided into two doses) as an adjunct therapy on oxidative stress, inflammatory markers and clini...
Detailed Description
Patient written informed consent will be taken prior to study conductance * Lab assessment will be done at baseline and at the end of the study by withdrawing 7 ml of whole blood for assessment of fo...
Eligibility Criteria
Inclusion
- Males or females aged 18-50 years diagnosed with Type 2 Diabetes taking oral hypoglycemic with controlled at HbA1c (6%-7%.)
- Patients diagnosed with Diabetic Neuropathy (by pinprick, temperature probe, ankle reflex, and vibration perception (128-Hz tuning fork) or pressure sensation (10 g monofilament test).
Exclusion
- Patients with acute and chronic inflammatory conditions, consuming any antioxidant supplements or anti-inflammatory medicines.
- Pregnancy or lactation or expecting to get pregnant during the study.
- Medical, psychological, or pharmacological factors interfering with the collection or interpretation of study data.
- Cancer patients.
- Anyone having hypersensitivity to N-acetylcysteine.
- Anyone already taking N-acetylcysteine.
Key Trial Info
Start Date :
December 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04766450
Start Date
December 1 2021
End Date
December 1 2022
Last Update
August 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Demerdash Hospital
Cairo, Egypt, 02